Detalhe da pesquisa
1.
Oxidative-Reductive Near-Infrared Electrochromic Switching Enabled by Porous Vertically Stacked Multilayer Devices.
J Am Chem Soc
; 145(24): 13411-13419, 2023 Jun 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-37279083
2.
Prevalence and Natural History of Segmental Colitis Associated With Diverticulosis.
Am J Gastroenterol
; 118(11): 2088-2092, 2023 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37314163
3.
Anthradithiophene (ADT)-Based Polymerized Non-Fullerene Acceptors for All-Polymer Solar Cells.
Chemistry
; 29(45): e202300653, 2023 Aug 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37191934
4.
Prognostic performance of the 'DICA' endoscopic classification and the 'CODA' score in predicting clinical outcomes of diverticular disease: an international, multicentre, prospective cohort study.
Gut
; 71(7): 1350-1358, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34702716
5.
Recent Advances in Non-Fullerene Acceptors of the IDIC/ITIC Families for Bulk-Heterojunction Organic Solar Cells.
Int J Mol Sci
; 21(21)2020 Oct 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-33138257
6.
Development and validation of an endoscopic classification of diverticular disease of the colon: the DICA classification.
Dig Dis
; 33(1): 68-76, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-25531499
7.
Diverticular Inflammation and Complication Assessment classification, CODA score and fecal calprotectin in clinical assessment of patients with diverticular disease: A decision curve analysis.
United European Gastroenterol J
; 11(7): 642-653, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37550901
8.
Real-world efficacy and safety of vedolizumab in managing ulcerative colitis versus Crohn's disease: results from an Italian multicenter study.
Expert Opin Biol Ther
; 23(3): 293-304, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36843568
9.
Comparison of Performances of Adalimumab Biosimilars SB5, ABP501, GP2017, and MSB11022 in Treating Patients with Inflammatory Bowel Diseases: A Real-Life, Multicenter, Observational Study.
Inflamm Bowel Dis
; 29(3): 376-383, 2023 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35579320
10.
Use of tofacitinib as first or second-line therapy is associated with better outcomes in patients with ulcerative colitis: data from a real-world study.
Expert Opin Pharmacother
; 24(14): 1649-1656, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37358928
11.
Replacement of Adalimumab Originator to Adalimumab Biosimilar for a Non-Medical Reason in Patients with Inflammatory Bowel Disease: A Real-life Comparison of Adalimumab Biosimilars Currently Available in Italy.
J Gastrointestin Liver Dis
; 31(4): 411-416, 2022 12 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-36535057
12.
Comparison of performances of infliximab biosimilars CT-P13 versus SB2 in the treatment of inflammatory bowel diseases: a real-life multicenter, observational study in Italy.
Expert Opin Biol Ther
; 22(2): 313-320, 2022 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-34904510
13.
Long-term, Real-life, Observational Study in Treating Outpatient Ulcerative Colitis with Golimumab.
J Gastrointestin Liver Dis
; 30(4): 456-461, 2021 12 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-34812437
14.
Long-term real-life efficacy and safety of infliximab and adalimumab in the treatment of inflammatory bowel diseases outpatients.
Eur J Gastroenterol Hepatol
; 33(5): 670-679, 2021 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33741797
15.
Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study.
Am J Gastroenterol
; 105(10): 2218-27, 2010 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-20517305
16.
Vedolizumab is effective and safe in real-life treatment of inflammatory bowel diseases outpatients: A multicenter, observational study in primary inflammatory bowel disease centers.
Eur J Intern Med
; 66: 85-91, 2019 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-31208827
17.
Infliximab biosimilar CT-P13 is effective and safe in treating inflammatory bowel diseases: a real-life multicenter, observational study in Italian primary inflammatory bowel disease centers.
Ann Gastroenterol
; 32(4): 392-399, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31263362
18.
Effectiveness and safety of adalimumab to treat outpatient ulcerative colitis: A real-life multicenter, observational study in primary inflammatory bowel disease centers.
Medicine (Baltimore)
; 97(34): e11897, 2018 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-30142791
19.
Effectiveness and safety of infliximab biosimilar CT-P13 in treating ulcerative colitis: a reallife experience in IBD primary centers.
Minerva Gastroenterol Dietol
; 63(4): 313-318, 2017 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-28293938
20.
Effectiveness and Safety of Golimumab in Treating Outpatient Ulcerative Colitis: A Real-Life Prospective, Multicentre, Observational Study in Primary Inflammatory Bowel Diseases Centers.
J Gastrointestin Liver Dis
; 26(3): 239-244, 2017 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-28922435